Amylou Dueck, Ph.D.
Affiliations: | 2005 | Arizona State University, Tempe, AZ, United States |
Area:
StatisticsGoogle:
"Amylou Dueck"Parents
Sign in to add mentor| Sharon Lohr | grad student | 2005 | Arizona State | |
| (Robust imputation in multivariate hierarchical data.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Eiger D, Pondé NF, Agbor-Tarh D, et al. (2020) Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. British Journal of Cancer |
| Taarnhøj GA, Johansen C, Lindberg H, et al. (2020) Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Medicine |
| Huberty J, Eckert R, Dueck A, et al. (2019) Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. Bmc Complementary and Alternative Medicine. 19: 121 |
| Mascarenhas J, Lu M, Kosiorek H, et al. (2019) Oral Idasanutlin in Patients with Polycythemia Vera. Blood |
| Solinas C, Silva PD, Venet D, et al. (2019) Abstract 3132: Immune regulatory gene expression and clinical outcome in the NeoALTTO trial Cancer Research. 79: 3132-3132 |
| Macarulla Mercade T, Hendifar A, Li CP, et al. (2018) Health-related quality of life (HRQoL) in patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant chemotherapy (A/NAC): A systematic literature review (SLR). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii253 |
| Padrnos L, Ernst B, Dueck AC, et al. (2018) A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma & Leukemia |
| Chumsri S, Sperinde J, Liu H, et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Sonbol MB, Hilal T, Dueck AC, et al. (2018) A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia & Lymphoma. 1-7 |
| Gowin K, Kosiorek H, Dueck A, et al. (2017) Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis. Leukemia Research. 60: 31-35 |